Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia): Current insights, challenges, and strategic directions
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0319042 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Said El Shamieh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Testing Laboratory, Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon. Hauptthemen laut MEDLINE: Pharmacogenetics, Delivery of Health Care. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and objectives Pharmacogenomics (PGx) leverages genomic information to tailor drug therapies, enhancing precision medicine. Despite global advancements, its implementation in Lebanon, Qatar, and Saudi Arabia faces unique challenges in clinical integration. This study aimed to investigate PGx attitudes, knowledge implementation, associated challenges, forecast future educational needs, and compare findings across the three countries.
Methods
This cross-sectional study utilized an anonymous, self-administered online survey distributed to healthcare professionals, academics, and clinicians in Lebanon, Qatar, and Saudi Arabia. The survey comprised 18 questions to assess participants’ familiarity with PGx, current implementation practices, perceived obstacles, potential integration strategies, and future educational needs.
Results
The survey yielded 337 responses from healthcare professionals across the three countries. Data revealed significant variations in PGx familiarity and educational involvement. Qatar and Saudi Arabia participants were more familiar with PGx compared to Lebanon (83%, 75%, and 67%, respectively). Participation in PGx-related talks was most prevalent in Saudi Arabia (96%), followed by Qatar (53%) and Lebanon (35%). Key challenges identified included test cost and reimbursement, insufficient physician knowledge, and lack of infrastructure. Lebanon reported the highest concern for test costs (16%), compared to the lowest in Saudi Arabia (5%). Despite these challenges, a strong consensus emerged on PGx’s potential to improve patient outcomes, with over 86% of respondents in all three countries expressing this belief. Educational interest areas varied by country, with strong interest in PGx for cancer chemotherapy in Saudi Arabia and Lebanon and for diabetes mellitus in Qatar.
Conclusion
This study highlights the significant influence of varied educational backgrounds and infrastructural limitations on PGx implementation across Lebanon, Qatar, and Saudi Arabia. The findings emphasize the need for targeted strategies in each country to address these distinct barriers. Integrating PGx education into healthcare training programs and clinical workflows could unlock PGx’s potential to optimize patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Molecular Testing Laboratory, Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
- Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
- QU Health, Qatar University, Doha, Qatar.
- Clinical and Pharmacy Practice Department, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
- Department of Nursing, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon.
- Department of Biomedical Sciences, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
ORCID-Profile: Said El Shamieh, Rajaa Fakhoury
Zitieren
APA
El Shamieh, S., Saleem, R. A., Hammoudi Halat, D., Fakhoury, H. M. A., Bastaki, K., Fawaz, M., Malki, A., & Fakhoury, R. (2025). Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia): Current insights, challenges, and strategic directions. PLOS ONE. https://doi.org/10.1371/journal.pone.0319042
Vancouver
El Shamieh S, Saleem RA, Hammoudi Halat D, Fakhoury HMA, Bastaki K, Fawaz M, et al. Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia): Current insights, challenges, and strategic directions. PLOS ONE. 2025. doi:10.1371/journal.pone.0319042
BibTeX
@article{ElShamieh2025,
author = {El Shamieh, Said and Saleem, Rimah Abdullah and Hammoudi Halat, Dalal and Fakhoury, Hana M A and Bastaki, Kholoud and Fawaz, Mirna and Malki, Ahmed and Fakhoury, Rajaa},
title = {Integrating pharmacogenomics in three Middle Eastern countries’ healthcare (Lebanon, Qatar, and Saudi Arabia): Current insights, challenges, and strategic directions},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0319042}
}
EUVIMED